吕万良研究团队揭示了一种新的雌激素受体阳性乳腺癌基因增强子

中国药学(英文版) ›› 2022, Vol. 31 ›› Issue (9): 723-724.

吕万良研究团队揭示了一种新的雌激素受体阳性乳腺癌基因增强子

北京大学药学院天然药物及仿生药物国家重点实验室

北京大学药学院天然药物及仿生药物国家重点实验室

收稿日期:2022-09-15 修回日期:2022-09-16 接受日期:2022-09-17 出版日期:2022-09-30 发布日期:2022-10-03

The research group of Prof. Wanliang Lu revealed a novel oncogenic enhancer of estrogen receptor-positive breast cancer

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center

Received:2022-09-15 Revised:2022-09-16 Accepted:2022-09-17 Online:2022-09-30 Published:2022-10-03

摘要/Abstract

摘要： 9月6日, 北京大学药学院天然药物及仿生药物国家重点实验室吕万良课题组在国际学术期刊《Molecular Therapy-Nucleic Acids》发表了题为A novel oncogenic enhancer of estrogen receptor-positive breast cancer的研究工作。

Supporting:

北京大学药学院天然药物及仿生药物国家重点实验室. 吕万良研究团队揭示了一种新的雌激素受体阳性乳腺癌基因增强子[J]. 中国药学(英文版), 2022, 31(9): 723-724.

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center. The research group of Prof. Wanliang Lu revealed a novel oncogenic enhancer of estrogen receptor-positive breast cancer[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(9): 723-724.